Latest Conference Articles

One expert explains why “the future of precision medicine” has arrived in lung cancer at the CURE® Educated Patient® Lung Cancer Summit.

Tumor characteristics are used to determine the best method of combining therapies with surgery for non-small cell lung cancer, according to a presentation at the CURE® Educated Patient® Lung Cancer Summit.

During the CURE® Educated Patient® Multiple Myeloma Summit, one expert explained the push to make CAR-T cell therapy available for patients sooner.

Radiation plus targeted or immunotherapies could be beneficial for certain patients with lung cancer, and expert said at the CURE® Educated Patient® Lung Cancer Summit.

Patients with lung cancer may have personalized treatment options after biomarker testing, an expert said at the CURE® Educated Patient® Lung Cancer Summit.

Treatment for lung cancer has changed significantly with immunotherapy, an expert said during the CURE® Educated Patient® Lung Cancer Summit.

Data show that patients’ multiple myeloma still fails to progress if patients receive less-frequent Tecvayli.

To ensure best outcomes, patients with chronic myeloid leukemia should maintain frequent communication with their care teams — even between appointments.

Most — though not all — side effects from chronic myeloid leukemia treatment improve over time, an expert said.

A chronic myeloid leukemia diagnosis can negatively affect patients and their loved ones’ mental health, but there are resources that can help.

As part of the CURE® Educated Patient® Summit, one expert reviewed the landscape of bispecific antibodies, such as Tecvayli, for multiple myeloma.

Patients with chronic myeloid leukemia should be upfront with their care team about how treatment side effects are affecting their daily functioning.

Quality of life may temporarily worsen after patients with myeloma receive stem cell transplants, said an expert at the Educated Patient® Multiple Myeloma Summit.

Initial discussions about treatment, side effects and study results can help patients navigate through all aspects of a chronic myeloid leukemia diagnosis.

An advocate discusses vital patient-provider conversations to promote the best care for individuals with chronic myeloid leukemia.

For patients with non-small lung cancer and brain metastases, it’s important to consent to shaving the scalp before tumor-treating fields therapy.

New drug combinations and sequences are being investigated and may improve outcomes for patients with newly diagnosed myeloma, an expert explained at the Educated Patient® Multiple Myeloma Summit.

Data from the MajesTEC-1 trial shows that patients with relapsed/refractory multiple myeloma responded to Tecvalyi for a median of two years and lived without disease progression for nearly a year.

Sarclisa, Velcade, Revlimid and dexamethasone improved progression-free survival in patients with multiple myeloma who were not eligible for transplant.

Patients with resectable stage 3 melanoma should talk about pretreatment therapy with their cancer care teams, an expert said.

Padcev and Keytruda improve survival and progression among patients with bladder cancer, but don’t adversely impact pain, functioning or quality of life.

Trodelvy led to better disease control and improved quality of life compared to chemotherapy in patients with triple-negative breast cancer.

Keytruda plus platinum-based chemotherapy appeared to be safe and effective in treating penile squamous cell carcinoma.

For patients with cisplatin-ineligible bladder cancer, presurgical Padcev decreased the cancer stage without leading to delays in surgery.

Some patients with stage 3 non-small cell lung cancer saw benefits from Opdivo plus chemotherapy followed by surgery then Opdivo, researchers found.

Dato-DXd was efficacious in patients with non-small cell lung cancer with brain metastases who have certain gene alterations, a phase 2 study showed.

PolyPEPI1018 may boost the efficacy of Tecentriq in certain patients with colorectal cancer.

Belamaf plus bortezomib and dexamethasone lengthened the time patients with relapsed or refractory myeloma lived before their disease got worse.

Zanidatamab continued to lead to responses and improved overall survival in pretreated HER2-positive biliary tract cancer.

Patients with myelodysplastic syndromes tended to have longer periods of time without needing a red blood cell transfusion when treated with Reblozyl.